https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Comparing mismatch strategies for patients being considered for ischemic stroke tenecteplase trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38851 15 mL, mismatch ratio > 1.8 and ischemic core < 70 mL). We then investigated whether tenecteplase-treated patients had favorable odds of less disability (on modified Rankin scale, mRS) compared to those treated with alteplase, for clinical and imaging mismatch, respectively. Results: From 146 pooled patients, 71 received alteplase and 75 received tenecteplase. The overall pooled group did not show improved patient outcomes when treated with tenecteplase (mRS 0-1 OR 1.77, 95% CI 0.89–3.51, p = 0.102) compared with alteplase. A total of 39 (27%) patients met both clinical and imaging mismatch criteria, 25 (17%) patients met only imaging criteria, 36 (25%) met only clinical mismatch criteria and, finally, 46 (31%) did not meet either of imaging or mismatch criteria. Patients treated with tenecteplase had more favorable outcomes when they met either imaging mismatch (mRS 0–1, OR 2.33, 95% CI 1.13–5.94, p = 0.032) or clinical mismatch criteria (mRS 0–1, OR 2.15, 95% CI 1.142, 8.732, p = 0.027) but with differing proportions. Conclusion: Target mismatch selection was more inclusive and exhibited in a larger treatment effect between tenecteplase and alteplase.]]> Wed 16 Feb 2022 15:17:26 AEDT ]]> Fatigue-sensitive afferents inhibit extensor but not flexor motoneurons in humans https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3785 Wed 11 Apr 2018 14:35:35 AEST ]]> Key mechanisms underlying damage and repair processes in sites of secondary neurodegeneration after ischemic stroke https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31256 Wed 11 Apr 2018 09:48:38 AEST ]]> Individual patient profiling using clinical and neuroradiological biomarkers in acute ischemic stroke: application of advanced multimodal neuroimaging https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29075 Tue 17 Sep 2019 15:21:28 AEST ]]> Growth hormone and neuronal hemoglobin in the brain-roles in neuroprotection and neurodegenerative diseases https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46328 Tue 15 Nov 2022 12:30:40 AEDT ]]> Acute stroke imaging research roadmap III imaging selection and outcomes in acute stroke reperfusion clinical trials: consensus recommendations and further research priorities https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25015 Thu 28 Oct 2021 13:02:55 AEDT ]]> Comparison of computed tomography perfusion and magnetic resonance imaging perfusion-diffusion mismatch in ischemic stroke https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21179 4 seconds for lesion region of interest. The MR-Tmax >6 seconds perfusion lesion was automatically segmented and registered to CTP. Receiver-operating characteristic analysis determined the optimal CT-Tmax threshold to match MR-Tmax >6 seconds. Agreement of these CT parameters with MR perfusion-diffusion mismatch in coregistered slabs was assessed (mismatch ratio >1.2, absolute mismatch >10 mL, infarct core <70 mL). Results: In analysis of 49 patients (mean onset to CT, 213 minutes; mean CT to MR, 31 minutes), constraining relCBF <31% within the automated relTTP perfusion lesion region of interest reduced the median magnitude of volumetric error (vs diffusion-weighted imaging) from 47.5 mL to 15.8 mL (P<0.001). The optimal CT-Tmax threshold to match MR-Tmax >6 seconds was 6.2 seconds (95% confidence interval, 5.6–7.3 seconds; sensitivity, 91%; specificity, 70%; area under the curve, 0.87). Using CT-Tmax >6 seconds “penumbra” and relTTP-constrained relCBF “core,” CT-based and MRI-based mismatch status was concordant in 90% (kappa=0.80). Conclusions: Quantitative CTP mismatch classification using relCBF and Tmax is similar to perfusion-diffusion MRI. The greater accessibility of CTP may facilitate generalizability of mismatch-based selection in clinical practice and trials.]]> Sat 24 Mar 2018 07:58:05 AEDT ]]> Ischemia and status epilepitcus result in enhanced phosphorylation of calcium and calmodulin-stimulated protein kinase II on threonine 253 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5540 Sat 24 Mar 2018 07:49:10 AEDT ]]> Hypoxic preconditioning in neonatal rat brain involves regulation of excitatory amino acid transporter 2 and estrogen receptor alpha https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:136 Sat 24 Mar 2018 07:43:14 AEDT ]]> Blood flow restricted exercise for athletes: a review of available evidence https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26156 Sat 24 Mar 2018 07:35:26 AEDT ]]> Are myocardial infarction-associated single-nucleotide polymorphisms associated with ischemic stroke? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25211 Sat 24 Mar 2018 07:14:02 AEDT ]]> Folate and MMA predict cognitive impairment in elderly stroke survivors: a cross sectional study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29834 Fri 22 Apr 2022 10:24:15 AEST ]]> Targeted Therapies for Microvascular Disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53867 Fri 19 Jan 2024 12:39:36 AEDT ]]> Targeted Therapies for Microvascular Disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53868 Fri 19 Jan 2024 12:38:51 AEDT ]]> Astrocyte Responses to Complement Peptide C3a are Highly Context-Dependent https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51514 Fri 08 Sep 2023 12:03:44 AEST ]]>